Background: The prevalence of hepatitis C virus (HCV) in U.S. prisoners is high; however, HCV testing and treatment are rare. Infected inmates released back into society contribute to the spread of HCV in the general population. Routine hepatitis screening of inmates followed by new therapies may reduce ongoing HCV transmission.

Objective: To evaluate the health and economic effect of HCV screening and treatment in prisons on the HCV epidemic in society.

Design: Agent-based microsimulation model of HCV transmission and progression of HCV disease.

Data Sources: Published literature.


Time Horizon: 30 years.

Perspective: Societal.

Interventions: Risk-based and universal opt-out hepatitis C screening in prisons, followed by treatment in a portion of patients.

Outcome Measures: Prevention of HCV transmission and associated disease in prisons and society, costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), and total prison budget.

Results of Base-Case Analysis: Implementing risk-based and opt-out screening could diagnose 41 900 to 122 700 new HCV cases in prisons in the next 30 years. Compared with no screening, these scenarios could prevent 5500 to 12 700 new HCV infections caused by released inmates, wherein about 90% of averted infections would have occurred outside of prisons. Screening could also prevent 4200 to 11 700 liver-related deaths. The ICERS of screening scenarios were $19 600 to $29 200 per QALY, and the respective first-year prison budget was $900 to $1 150 million. Prisons would require an additional 12.4% of their current health care budget to implement such interventions.

Results of Sensitivity Analysis: Results were sensitive to the time horizon, and ICERS otherwise remained less than $50 000 per QALY.

Limitation: Data on transmission network, reinfection rate, and opt-out HCV screening rate are lacking.

Conclusion: Universal opt-out HCV screening in prisons is highly cost-effective and would reduce HCV transmission and HCV-associated diseases primarily in the outside community. Investing in U.S. prisons to manage hepatitis C is a strategic approach to address the current epidemic.

Primary Funding Source: National Institutes of Health.
METHODS

We developed the TapHCV (treatment as prevention of hepatitis C virus) model, an agent-based microsimulation model that projects the long-term benefits and costs of different HCV screening and treatment scenarios in U.S. prisons. Our model includes HCV transmission, the natural history of HCV based on a previously validated Markov model (21), HCV screening in inmates, treatment of HCV infection with DAAs, and movement of people in and out of prisons. We simulated the disease and its progression both in prisons and in the general population to understand the complex dynamics between prison-related interventions and disease burden in society as a whole (Figure 1). The model was developed in the Java programming language (Oracle Java SE Development Kit 7) from a societal perspective with a 30-year time horizon using monthly cycles (see Supplement, available at www.annals.org).

Baseline Population

We simulated 2 million heterogeneous individuals representing the U.S. population inside and outside of prisons in 2015. Patient characteristics included age, sex, drug use behavior (active or former IDU versus non-IDU), and imprisonment status (incarcerated in state or federal prisons versus general population). Prisoners constituted 0.5% of the total U.S. population, and 91% were male (Supplement Tables 1 and 2, available at www.annals.org) (22). We stratified HCV prevalence by individuals’ characteristics. We also defined the baseline distribution of common U.S. HCV genotypes (1, 2, 3, and 4), chronic HCV stage using METAIR fibrosis scores (no fibrosis [F0], portal fibrosis without septa [F1], portal fibrosis with few septa [F2], numerous septa without cirrhosis [F3], or compensated cirrhosis [F4]), and treatment history (previously treated or treatment-naive) using published studies (Supplement Tables 3 and 4, available at www.annals.org). In the base case, we assumed that 25% of HCV-infected patients in prisons and 50% outside were aware of their disease status through prior community or prison screening. A more detailed description of the baseline population is provided in the Supplement.

HCV Transmission and Progression

During each month, infected individuals could transmit the virus to uninfected individuals. We modeled 2 kinds of transmissions, separately in prisons and community: 1) IDU-related and 2) all other types of transmission. The probability of transmission depended on the following factors: awareness status, active IDU, history of IDU, and prior HCV treatment (Supplement and Supplement Table 5, available at www.annals.org). We calibrated transmission-related measures that were not directly available by choosing those that produced incidence results observed and published by the Centers for Disease Control and Prevention (Supplement). We assumed that the likelihood of HCV transmission was 50% lower for persons who were aware of their infection status. All newly infected individuals started with the acute phase of HCV infection, which could develop into the chronic phase. We defined the natural history of HCV using Markov health states, which was based on our previously published models (21, 23). The chronic disease progressed to different stages of fibrosis, as defined by METAIR fibrosis scores, from F0 to F4 (Figure 1). Patients at METAIR score a F3 and F4 could develop decompensated cirrhosis, hepatocellular carcinoma, or both. Patients with decompensated cirrhosis or hepatocellular carcinoma might receive a liver transplant or die of a liver-related condition (Supplement Table 6, available at www.annals.org). We also applied a background mortality adjusted by age, sex, and IDU (Supplement).

HCV Screening

Unaware patients could be diagnosed through HCV testing. We evaluated 5 screening scenarios in prisons starting from the year 2015: no screening; 1-time risk-based screening of currently incarcerated...
persons and entrants with active or former IDU for 1 year (1Yr-Risk); and 1-time opt-out universal HCV screening of currently incarcerated inmates followed by opt-out screening of all incoming inmates for up to 1 year (1Yr-All), 5 years (5Yr-All), and 10 years (10Yr-All). We assumed that the uptake rate of risk-based screening was 75% (on the basis of the Arrestee Drug Abuse Monitoring jail study) and that the rate of opt-out HCV screening was 90%, similar to that of HIV opt-out screening in prisons (24, 25). In the general population, we implemented a combination of birth-cohort and risk-based screening, the current standard of care (Supplement Table 7, available at www.annals.org).

**HCV Treatment**

Inmates diagnosed with HCV were eligible for treatment with recently approved DAAAs. In the base case, we assumed that only those with METAVIR fibrosis scores of F3 and F4 would receive treatment and that others would wait because of limited resources. We assumed that those in stages F0 to F2 would undergo annual aspartate aminotransferase-to-platelet ratio index tests and become eligible for treatment if they advanced to F3 (26). Patients were assigned to treatment with oral DAAs, as defined by the clinical guidelines (27). Because the sustained viral response (SVR) rates of the available oral drugs are similar to each other, we used the SVR rates of sofosbuvir-based therapies as a reference. Treatment regimen depended on HCV genotype, previous treatment outcomes, and presence of cirrhosis (Supplement Table 8, available at www.annals.org). We assumed that in 2030, generic drugs would become available and that all patients would be eligible for treatment with low-cost drugs regardless of their fibrosis stage (28).

**Admission and Release of Prisoners**

We simulated movement of people from the community to prisons and vice versa (Figure 1). The probability of being incarcerated and lengths of sentence at admission were estimated from pooled data from the Bureau of Justice Statistics and published reports (Supplement and Supplement Tables 9 and 10, available at www.annals.org).

**Costs and Utilities**

Our model included the cost of HCV testing, antiviral treatment, and management of chronic HCV dis-

---

**Figure 1. Model schematic of HCV transmission and progression in prisons and in the general population.**

The schematic of our agent-based model shows the prison population and general population and the dynamic movement between the 2 groups (dashed arrows). Each person is defined by demographic characteristics, liver stage, and IDU. As time progresses, the following characteristics are updated: age, IDU status, HCV infection status (infected individuals shown in black), stage of liver disease, and location (inside or outside prison). HCV-infected persons can transmit disease to others in their immediate network (solid arrows). The natural history of chronic HCV disease is represented by Markov states (top right inset). Stages of chronic HCV disease are defined by METAVIR fibrosis scores. Advanced liver diseases stages are DC, HCC, LT, and LRDs. DC = decompensated cirrhosis; F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with few septa; F3 = numerous septa without cirrhosis; F4 = compensated cirrhosis; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IDU = injection drug use; LRD = liver-related death; LT = liver transplantation.
ease (Supplement Table 11, available at www.annals.org). Screening costs included those of HCV antibody, HCV RNA, and HCV genotype testing and of the FibroSure test (LabCorp). Treatment costs included the wholesale acquisition costs of sofosbuvir ($7000 per week), ledipasvir ($1125 per week), and ribavirin ($309 per week) (29), and we considered drug discounts in sensitivity analysis (30). Costs of HCV disease management included the cost associated with chronic HCV infection, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation. All costs were converted to 2014 U.S. dollars.

To each individual in our model, we assigned health-related quality-of-life weights, with 0 denoting death and 1 denoting perfect health, and adjusted them by IDU, age, and sex (Supplement Table 12, available at www.annals.org). We assumed that the quality of life of patients who achieved SVR was equivalent to that of uninfected persons if they had METAVIR scores of F0 or F1 and was worse than that of uninfected persons otherwise.

Model Outcomes
For each screening scenario, we projected the number of HCV cases diagnosed, the number of new HCV infections resulting from the release of untreated, HCV-infected inmates; quality-adjusted life-years (QALYs); and total cost to prisons and society, including the cost of HCV screening, antiviral treatment, and HCV disease and its sequelae (such as cases of decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related deaths). We further estimated the benefits gained in the community due to screening in prisons. Finally, we estimated the incremental cost-effectiveness ratios (ICERs) of all screening scenarios. We applied a standard 3% annual discount rate to all future costs and QALYs and ran our model 40 times (Monte Carlo runs) to estimate 95% CIs of outcomes. Our analysis followed the recommendations of the U.S. Panel on Cost-Effectiveness in Health and Medicine (31).

We also performed a subgroup cost-effectiveness analysis by excluding any health benefits gained while the individual was incarcerated and considered only the benefits gained while the individual was in the community that were due to screening in prisons.

To evaluate the robustness of the model results to uncertainty in input parameters, we performed sensitivity analyses on baseline population characteristics, transition probabilities, behavior inputs, quality-of-life utilities, SVR rates, all costs (including the cost of treatment), and patent expiration year. We also conducted scenario analyses on the time of HCV treatment in prisons.

Validation
We performed external validation of the TapHCV model by comparing intermediate model outcomes with known data. Specifically, we validated the natural history of HCV in the model by comparing the projected incidence rates of hepatitis C sequelae to the reported range of a large clinical study (Supplement and Supplement Table 13, available at www.annals.org). We also validated the projected number of admissions to U.S. prisons with the Bureau of Justice Statistics data (Supplement and Supplement Table 14, available at www.annals.org).

Role of the Funding Source
The funding source had no role in the design, conduct, or analysis of the study or in the decision to submit the manuscript for publication.

RESULTS
HCV Diagnosis in Prisons
Implementing risk-based screening of entering and currently incarcerated active or former IDUs for 1 year (1Yr-Risk) could diagnose 41 900 (95% CI, 40 700 to 43 200) new HCV cases among prisoners in the next 30 years. In comparison, the 1Yr-All, 5Yr-All, and 10Yr-All scenarios could diagnose 81 100 (CI, 79 600 to 82 700), 106 600 (CI, 104 700 to 108 500), and 122 700 (CI, 120 800 to 124 600) new HCV cases, respectively, of which 70 700 (CI, 69 000 to 72 300) would be diagnosed among inmates currently incarcerated. The screening cost per case identified under the 1Yr-Risk, 1Yr-All, 5Yr-All, and 10Yr-All strategies would be $880, $1300, $1680, and $2030, respectively.

Prevention of HCV Disease
Compared with the no-screening scenario, the 1Yr-Risk, 1Yr-All, 5Yr-All, and 10Yr-All scenarios would prevent 5500 (CI, 4400 to 6600), 8000 (CI, 6800 to 9000), 10 900 (CI, 9700 to 12 000), and 12 700 (CI, 11 500 to 13 900) new HCV infections, respectively, in the next 30 years. Of these cases prevented by prison screening programs, 89% to 92% of averted infections would have occurred in the general population (Figure 2, top). For all scenarios, infections averted would peak between years 2020 and 2024 and decline afterward (Supplement Figure 1, available at www.annals.org). Interventions in prisons would reduce the number of HCV-infected people in prisons over time, and the benefits of screening would peak around year 2035 and decline afterward (Supplement Figure 2, available at www.annals.org). Furthermore, compared with no screening, HCV screening in prisons could prevent 4200 to 11 700 liver-related deaths, 300 to 900 liver transplantations, 3000 to 8600 cases of hepatocellular carcinoma, and 2600 to 7300 cases of decompensated cirrhosis in the next 30 years. Of note, among liver-related deaths averted, 80% would have occurred in the outside community.

Reduction in HCV Disease Cost
Compared with the no-screening scenario, the 1Yr-Risk, 1Yr-All, 5Yr-All, and 10Yr-All scenarios would reduce HCV disease cost due to in-prison management of released inmates by $260 (CI, $220 to $300) million, $510 (CI, $470 to $560) million, $680 (CI, $620 to $740) million, and $760 (CI, $700 to $820) million, respectively (Figure 2, bottom). Reductions in HCV disease cost in the general population constituted 82% to 84%...
of the total savings stemming from screening in prisons. Of the total cost savings, 42% to 44% were due to fewer cases of decompensated cirrhosis, 39% were due to fewer cases of hepatocellular carcinoma, and 17% to 19% were due to fewer liver transplantations.

**Cost-Effectiveness Analysis**

Compared with the no-screening scenario, the 1Yr-Risk, 1Yr-All, 5Yr-All, and 10Yr-All scenarios would increase the total QALYs by 41 900 (CI, 37 700 to 46 100), 75 600 (CI, 69 600 to 81 600), 95 800 (CI, 89 000 to 102 700), and 105 700 (CI, 99 200 to 112 200), respectively. The corresponding increase in total costs would be $820 (CI, $760 to $890) million, $1520 (CI, $1440 to $1590) million, $2000 (CI, $1920 to $2090) million, and $2290 (CI, $2220 to $2370) million, respectively. The ICERs of the 1Yr-Risk, 1Yr-All, 5Yr-All, and 10Yr-All strategies were $19 600, $20 600, $24 000, and $29 200 per additional QALY, respectively.

Next, we estimated the benefit of interventions in prison on the society exclusively by excluding the QALYs gained inside prisons and considering only QALYs gained in the community. The estimated increase in QALYs due to 1Yr-Risk, 1Yr-All, 5Yr-All, and 10Yr-All screening were 35 600 (CI, 31 500 to 39 600), 64 900 (CI, 59 300 to 70 500), 82 100 (CI, 75 900 to 88 400), and 90 300 (CI, 84 300 to 96 300), respectively. The corresponding ICERs were $23 100, $23 600, $28 200, and $35 400 per additional QALY, respectively.

**Budget Effect on Prison System**

The first-year cost of HCV screening, treatment, and management of chronic hepatitis C in 2015 under risk-based screening and opt-out screening would be $900 million and $1146 million, respectively, spread over the prison systems in all states. The corresponding costs would decrease below 66 million after 15 years (Figure 3 and Supplement Figure 3, available at www.annals.org). The first-year budget needed to implement universal opt-out screening followed by treatment with DAAs would require an additional 12.4% over the current health care budget of state and federal prisons (32, 33). However, after 15 years, prisons would need only an additional 0.7% of the current health care budget because of a decrease in HCV prevalence in both prisons and society.

**Sensitivity Analysis**

We performed 1-way sensitivity analysis on all key model parameters (Supplement Tables 15 to 19, available at www.annals.org). Time horizon was the most sensitive parameter and could influence the cost-effectiveness of opt-out HCV testing (Figure 4). For all other parameters, the ICERs always remained less than $50 000 per QALY, indicating that uncertainty in model parameters did not influence the cost-effectiveness results. Of note, discounts on antiviral drugs would make HCV screening highly cost-effective. Treatment of HCV in early stages and immediately after diagnosis also resulted in ICERs less than $50 000 per QALY (Supplement Tables 20 and 21, available at www.annals.org).

**Discussion**

Our results suggest that universal opt-out screening of inmates for HCV is highly cost-effective for at least 10 years and would reduce ongoing HCV transmission, the incidence of advanced liver diseases, and liver-related deaths. Most of the benefits of interventions in prisons would accrue in the community because a larger proportion of releases to the community would have been cured of the disease. However, to achieve these benefits, the government needs to pro-
provide additional resources to prison health care, which will be a good investment for society.

Earlier research found that HCV treatment with DAAs is cost-effective in prison settings (16). However, the benefits of treatment would be incurred only if an effective screening policy is in place and HCV cases are diagnosed in a timely manner. To our knowledge, our study is the first to evaluate the society-wide benefits and cost-effectiveness of opt-out screening for hepatitis C in prisons. We developed a comprehensive mathematical model to simulate HCV transmission and interactions between prisons and community, thereby evaluating complex emergent dynamics that otherwise could not be predicted (34).

In 2012, the U.S. Preventive Services Task Force and the Centers for Disease Control and Prevention updated their HCV screening policies to include persons born between 1945 and 1965 (12, 35). Modeling studies have shown that HCV screening in the birth cohort is highly cost-effective. Our conclusions are based on widespread emergent dynamics that otherwise could not be predicted (34).

We used the model to evaluate the impact of HCV screening in prisons. We found that HCV screening in prisons was lower than that of the birth-cohort screening in the general population, which ranged from $35 700 to $65 700 per QALY (36, 39–41). Even after exclusion of all health benefits gained during time spent in prison, opt-out HCV screening still remained highly cost-effective. Our conclusions are based on wholesale acquisition costs of HCV treatment; however, in practice, several prisons would get drug discounts that would make HCV testing even more cost-effective.

Because U.S. correctional systems cannot display deliberate indifference to apparent health care needs (19, 42), without adequate health care budgets health administrators in prisons may be reluctant to identify all hepatitis C patients.

### Table. 30-y Cumulative Incidences of Infection, Advanced Diseases, and Results of Cost-Effectiveness Analysis*

<table>
<thead>
<tr>
<th>Variable</th>
<th>No Screening</th>
<th>1Yr-Risk vs. No Screening</th>
<th>1Yr-All vs. No Screening</th>
<th>5Yr-All vs. No Screening</th>
<th>10Yr-All vs. No Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1Yr-Risk</td>
<td>5Yr-All</td>
<td>10Yr-All</td>
<td></td>
</tr>
<tr>
<td>30-y cumulative incidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total HCV infections</td>
<td>166 084</td>
<td>−5508</td>
<td>−8041</td>
<td>−11 005</td>
<td>−12 607</td>
</tr>
<tr>
<td>Decompensated cirrhosis</td>
<td>633 235</td>
<td>−2476</td>
<td>−4532</td>
<td>−6218</td>
<td>−6908</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>730 683</td>
<td>−2930</td>
<td>−5665</td>
<td>−7519</td>
<td>−8602</td>
</tr>
<tr>
<td>Liver transplants</td>
<td>92 596</td>
<td>−187</td>
<td>−595</td>
<td>−702</td>
<td>−809</td>
</tr>
<tr>
<td>Liver-related deaths</td>
<td>780 803</td>
<td>−4310</td>
<td>−7942</td>
<td>−10 368</td>
<td>−11 730</td>
</tr>
<tr>
<td>30-y total cost, $ (million)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening cost</td>
<td>0.0</td>
<td>+37</td>
<td>+107</td>
<td>+178</td>
<td>+249</td>
</tr>
<tr>
<td>Treatment cost</td>
<td>59 035</td>
<td>+816</td>
<td>+1480</td>
<td>+1951</td>
<td>+2190</td>
</tr>
<tr>
<td>Cost of advanced HCV complications</td>
<td>94 326</td>
<td>−30</td>
<td>−71</td>
<td>−128</td>
<td>−148</td>
</tr>
<tr>
<td>Cost-effectiveness analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QALYs</td>
<td>5 677 199 951</td>
<td>+41 905</td>
<td>+33 696</td>
<td>+20 201</td>
<td>+9 898</td>
</tr>
<tr>
<td>Total cost, $ (million)</td>
<td>153 361</td>
<td>+823</td>
<td>+693</td>
<td>+486</td>
<td>+289</td>
</tr>
<tr>
<td>ICER, $/QALY</td>
<td>−19 635</td>
<td>20 571</td>
<td>24 046</td>
<td>29 234</td>
<td></td>
</tr>
</tbody>
</table>

* 1Yr-Risk = 1-time risk-based screening of currently incarcerated inmates and entrants for 1 y; 1Yr-All = 1-time opt-out screening of currently incarcerated inmates and entrants for 1 y; 5Yr-All = 1-time opt-out screening of currently incarcerated inmates and entrants for 10 y; 10Yr-All = 1-time opt-out screening of currently incarcerated inmates and entrants for 10 y; No screening = No screening inside prisons; QALY = quality-adjusted life-year.

Shown is the budget needed to screen, treat HCV infection, and manage chronic hepatitis C in prisons under 1-time opt-out universal screening of currently incarcerated inmates and entrants for 10 y (10Yr-All scenario). The annual budget decreased substantially from $35 700 to $65 700 per QALY (36, 39–41). Even after exclusion of all health benefits gained during time spent in prison, opt-out HCV screening still remained highly cost-effective. Our conclusions are based on wholesale acquisition costs of HCV treatment; however, in practice, several prisons would get drug discounts that would make HCV testing even more cost-effective.
HCV cases (42). Our study emphasizes the benefits of state or federal government allocating additional resources to prisons to screen for and treat HCV infection. Such investment in prisons is beneficial from the societal perspective because early detection and treatment in correctional settings could prevent future need for treatment, which would occur predominantly in society among released inmates. Furthermore, these interventions would prevent ongoing viral transmission in the general community.

Our study has several limitations. First, not all parameters were available or were up to date, including the incidence of HCV infection inside prisons and arrest rates among people who inject drugs. Therefore, we indirectly estimated these parameters through calibration and tested them in the sensitivity analysis. Second, we made simplifying assumptions about future trends in incarceration, risk behavior, and birth and death rates, which could affect our results. Third, the effectiveness of new therapies in prison settings is unknown. However, studies of earlier treatments suggest that in-prison outcomes would be similar to those in clinical trials (17, 43). Opt-out HCV screening rate in prisons is not known; therefore, we assumed the rate to be similar to that of HIV testing in prisons. In addition, we ended our simulation at the end of 30 years with no additional benefit, which tends to underestimate the benefits of screening.

Because of lack of data on HCV transmission, we made simplifying assumptions about the modes of HCV transmission and types of social network structure. We did not model advanced social networks of IDUs or sexual contacts. We modeled IDU transmission explicitly and all other transmissions grouped separately (see Supplement). We used a simplified temporal network of IDUs and assumed that age and sex had no effect on IDU mixing. Finally, we did not consider the possibility of future new antiviral therapies, which could be even more effective and less expensive.

In conclusion, screening the incarcerated population would play an important role in reducing HCV burden society-wide. Therefore, HCV prevention efforts should have an increased focus on prison inmates. From a societal perspective, investing in U.S. prison health care to manage hepatitis C would be money well spent.

From the University of Pittsburgh, Pittsburgh, Pennsylvania; Tsinghua University School of Medicine, Beijing, China; University of Texas Health Science Center at Houston, Houston, Texas; Rollins School of Public Health, Emory University, and H. Milton Stewart School of Industrial and Systems Engineer--
Prevention of Hepatitis C in U.S. Prisons

...ing, Georgia Institute of Technology, Atlanta, Georgia; and Institute for Technology Assessment, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgment: The authors thank Kenneth Sherman and Rich Feffer for constructive comments that improved the quality of the manuscript and Jill Delsigne for editing the manuscript. Dr. Chhatwal had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Grant Support: In part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR000146. Dr. He’s effort was supported by the China Scholarship Council.

Disclosures: Dr. Chhatwal reports grants from National Institutes of Health during the conduct of the study, personal fees from Complete HEOR Solutions and Merck & Co., and grants and personal fees from Gilead Sciences outside the submitted work. Dr. Spaulding reports grants and personal fees from Gilead Sciences during the conduct of the study, personal fees from Janssen, grants from Boehringer, and grants from Bristol-Myers Squibb outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0617.

Reproducible Research Statement: Study protocol: Not applicable. Statistical code and data set: Available from Dr. Chhatwal (JagChhatwal@mgh.harvard.edu).

Requests for Single Reprints: Jagpreet Chhatwal, PhD, Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114; e-mail, jagchhatwal@mgh.harvard.edu.

Current author addresses and author contributions are available at www.annals.org.

References


Current Author Addresses: Dr. He: 602 Mingri Dasha, 69 DongDan North Street, Beijing, China, 100005.
Mr. Li: 1200 Herman Pressler Drive, RAS E-803N, Houston, TX 77030.
Dr. Roberts: 130 De Soto Street, Suite A621, Pittsburgh, PA 15261.
Dr. Spaulding: 1518 Clifton Road, Room 3033, Atlanta, GA 30322.
Dr. Ayer: 417 Groseclose Building, 765 Ferst Drive, Atlanta, GA 30332.
Dr. Grefenstette: 702A Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261.
Dr. Chhatwal: Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114.

Author Contributions: Conception and design T. Ayer, J. Chhatwal, J.J. Grefenstette, T. He, K. Li, M.S. Roberts.
Drafting of the article J. Chhatwal, T. He.
Critical revision for important intellectual content T. Ayer, J. Chhatwal, J.J. Grefenstette, T. He, K. Li, M.S. Roberts, A.C. Spaulding.
Final approval of the article T. Ayer, J. Chhatwal, J.J. Grefenstette, T. He, K. Li, M.S. Roberts, A.C. Spaulding.
Provision of study materials or patients J. Chhatwal.
Statistical expertise T. Ayer, J. Chhatwal, T. He, K. Li.
Obtaining of funding J. Chhatwal.
Collection and assembly of data J. Chhatwal, T. He, K. Li.